Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00253669 · ClinicalTrials.gov registry record
Risk Factors for Developing a Blood Clot in Patients Who Are Undergoing Cancer Treatment for Newly Diagnosed Gliomas
A clinical trial of Brain and Central Nervous System Tumors and Thromboembolism, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- 110
- Enrollment target
- 9
- Study locations
NCT00253669: Completed study of Brain and Central Nervous System Tumors and Thromboembolism, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
NCT00253669 is a study of Brain and Central Nervous System Tumors and Thromboembolism that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 110 participants, below the 181-participant average among 45 other Brain and Central Nervous System Tumors trials with a reported enrollment target (39% lower). The trial reports 9 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00253669, a study of Brain and Central Nervous System Tumors and Thromboembolism, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- 110 participants
- Enrollment target
- 9
- Study locations
Study Summary
RATIONALE: Patients with gliomas may be at risk for developing blood clots. Learning about the risk factors for developing blood clots may help doctors plan better treatment for gliomas. PURPOSE: This clinical trial is studying risk factors for developing blood clots in patients who are undergoing cancer treatment for newly diagnosed gliomas.
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
- OTHER physiologic testing
- PROCEDURE management of therapy complications
Study Locations (9)
Alabama
- Lurleen Wallace Comprehensive Cancer at University of Alabama - Birmingham - Birmingham
Florida
- H. Lee Moffitt Cancer Center and Research Institute at University of South Florida - Tampa
Georgia
- Winship Cancer Institute of Emory University - Atlanta
Maryland
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins - Baltimore
Massachusetts
- Massachusetts General Hospital - Boston
Michigan
- Josephine Ford Cancer Center at Henry Ford Hospital - Detroit
North Carolina
- Wake Forest University Comprehensive Cancer Center - Winston-Salem
Ohio
- Cleveland Clinic Taussig Cancer Center - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2005-04 |
| Est. Completion | 2009-08 |
What the finished NCT00253669 record still lists
NCT00253669 is an observational study that tracks outcomes without assigning an intervention. The registered 110 participants enrollment target is mid-sized for trials with a published cap, below the 181-participant average among 45 other Brain and Central Nervous System Tumors trials with a reported enrollment target (39% lower).
The record links to 2 conditions, with Brain and Central Nervous System Tumors appearing as the primary indexed condition, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT00253669 lists 9 locations in 9 states (Alabama, Florida, Georgia).
Frequently Asked Questions
What is clinical trial NCT00253669 about?
NCT00253669 is a clinical study titled "Risk Factors for Developing a Blood Clot in Patients Who Are Undergoing Cancer Treatment for Newly Diagnosed Gliomas". RATIONALE: Patients with gliomas may be at risk for developing blood clots. Learning about the risk factors for developing blood clots may help doctors plan better treatment for gliomas. PURPOSE: This clinical trial is studying risk factors for developing blood clots in patients who are undergoing ...
What is the current status of trial NCT00253669?
This trial is currently completed. The enrollment target is 110 participants. The study started on 2005-04. Estimated completion is 2009-08.
What conditions does trial NCT00253669 study?
This clinical trial studies the following conditions: Brain and Central Nervous System Tumors, Thromboembolism.
What interventions are being tested in trial NCT00253669?
The interventions under investigation include: laboratory biomarker analysis (OTHER), physiologic testing (OTHER), management of therapy complications (PROCEDURE).
Who is sponsoring clinical trial NCT00253669?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00253669 being conducted?
This trial has 9 study locations across Alabama, Florida, Georgia, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain and Central Nervous System Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00253669's enrollment target sits among peer trials
110 11th of 45 higher than 35 of 45 other Brain and Central Nervous System Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Brain and Central Nervous System Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
RECRUITING
-
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
ACTIVE NOT RECRUITING · Phase 3
-
Phase III Trial of Anaplastic Glioma Without 1p/19q Loss of Heterozygosity (LOH)
ACTIVE NOT RECRUITING · Phase 3
-
Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma
ACTIVE NOT RECRUITING · Phase 2
-
Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma
ACTIVE NOT RECRUITING · Phase 3
-
Developing Interview Questions to Estimate Workplace Exposure to Electric and Magnetic Fields
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01530373 · 110 participants · Phase 2
Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients
- NCT02379377 · 110 participants · Phase 1
18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant
- NCT02411773 · 110 participants · Phase 1
Sympatholysis in Chronic Kidney Disease
- NCT03190941 · 110 participants · Phase 1
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia